Yes, percentages for hyper-progressive disease do vary. Hence my conservative figure of 10%.
But it is hugely under-reported.
Thousands of patients have died prematurely in hundreds of ICI clinical trials. How is it that not a single ICI clinical trial, up until about a year ago, reported any occurrences of hyperprogression?
That 10% incidence rate would have been just the same in clinical trials, as is now being shown in targeted studies.
But investigators chose to remain blinkered, and just marked it down as non-response to the investigational drug, and ordinary disease progression.
Big Pharma and the the FDA are responsible for these thousands of deaths.
And now thousands are dying in regular clinical practice.
The largest study to date on hyperprogression and NSCLC found an incidence of HPD of 16%, and an ORR of 15%....
So you know what that means..
Yes, more likely to kill you than help you.
Other studies have found a much higher incidence of HPD than 10%.
And an arm of a recent clinical trial reported 100% (6 out of 6) subjects experiencing HPD.
Market Data 
Markets 
AI
